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51 abstract
Endoscopic retrograde cholangiopancreatography (ERCP) is the radiographic 
examination of the biliary and/or pancreatic ductus via endoscopically cannulated 
duodenal papilla. ERCP is one of the common procedures performed in the 
gastrointestinal (GI) endoscopy suite and for its successful performance adequate 
sedation and analgesia are rather necessary than desired. During the last decade 
propofol alone or in combination with an opioid replaced traditionally used 
benzodiazepines and became the most preferred sedative agent during ERCP. The 
method of choice for the safe and cost-effective sedation of patients with spontaneous 
respiration during GI endoscopy is still to be defined. Self administration of propofol 
by the patients (patient-controlled sedation, PCS) might be one of the possibilities 
of this kind. Dexmedetomidine has gained approval for procedural sedation of 
non-intubated patients and has been reported effective in the treatment of alcohol 
withdrawal. The suitability of dexmedetomidine for sedation of alcoholics during 
ERCP has not been previously evaluated.
Four prospective randomized control trials consisting of 293 ERCP patients 
were performed in the Endoscopy unit of the Helsinki University Central Hospital 
from January 2009 to January 2011. PCS was compared with anesthesiologist 
administered sedation (AAS) using manually adjusted propofol infusion (I) and 
target-controlled infusion (TCI) system (III). Remifentanil and alfentanil were 
compared double-blindly in sedative mixture for PCS (II) and dexmedetomidine 
was evaluated for sedation of patients with chronic alcoholism in placebo-controlled 
double-blind study (IV). 
In all studies (I-IV) self-administration device was adjusted to deliver 1ml 
single bolus-dose of propofol or propofol-opioid mixture without any lockout time, 
background infusion or total dose limitation. PCS was considered as successful if 
propofol was not administered by anesthesiologist and/or ERCP was not interrupted 
due to sedation related complication. Loading dose of 1 mcg · kg-1 of dexmedetomidine 
was infused 10 minutes before ERCP start thereafter maintenance infusion at the 
constant rate of 0.7 mcg · kg-1 · h-1 was continued until the end of procedure (IV). 
In control groups sedation was administered by anesthesiologist with the use of 
manually adjusted propofol infusion (I) or target- controlled propofol infusion with 
initial effect effect-site concentration 2 mcg · ml-1 (III). Patients were monitored 
according to the standard of monitoring for deep sedation. Additionally end-tidal 
carbon dioxide and sedation levels with the use of sedation scales were followed. 
Hypoxemia (peripheral oxygen saturation below 90 % of any duration), respiratory 
depression (respiratory rate< 6 /min), hypotension (systolic blood pressure below 
690 mmHg), arrhythmia, and pulmonary aspiration were considered as sedation 
related adverse events (SRAE).
Consumption of propofol was the main outcome measure in all studies. 
Secondary objectives were success rate of PCS, SRAE, patient satisfaction with 
sedation, easiness of ERCP performance, and rapidity of the recovery. 
With the use of PCS propofol consumption was significantly lesser than with 
AAS using either manually adjusted or target-controlled propofol infusion. The 
success rate of PCS was 88 -100 %. The incidence of SRAE, easiness of ERCP 
performance, and patient satisfaction with sedation were similar during PCS and 
AAS. Patients who received PCS gained faster recovery than those who received 
AAS. Both alfentanil and remifentanil showed good suitability for PCS during 
ERCP without significant difference in propofol consumption, patient satisfaction 
and rapidity of the recovery. However, in combination with propofol remifentanil 
depressed spontaneous respiration more frequently and produced significantly more 
nausea post-procedurally. Increase of alfentanil concentration in sedative mixture 
from 0.04 mg · ml-1 to 0.08 mg · ml-1 did not provide any demonstrable benefit. 
The studied regimen of dexmedetomidine administration showed poor suitability 
for sedation of alcoholics during ERCP either alone or in combination with PCS 
because of prolonged induction of sedation, insufficient sedative effect, significant 
reduction of PCS success rate and slow recovery. Instead, PCS with propofol and 
alfentanil might be very successful for sedation of alcoholics during ERCP. 93 % of 
patients preferred PCS as a sedation method for possible future ERCP.
In conclusion, PCS with combination of propofol and alfentanil is recommended 
as a primary method of sedation during ERCP. 
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83 abbreviations
AAS = anesthesiologist administered sedation;
ASA = American Society of Anesthesiology;
BMI = body mass index;
CI = confidence interval;
CE = effect-site concentration;
CP = plasma concentration;
CV = coefficient of variation;
ECG = electrocardiography;
EGD = esofagogastroduodenoscopy;
ERCP = endoscopic retrograde cholangiopancreatography;
EtCO2 = end-tidal carbon dioxide;
EUS = endoscopic ultrasound;
ICU = intensive care unit;
ISTF = International Sedation Task Force;
GA = general anesthesia;
GI = gastrointestinal;
HR = heart rate;
l · min-1 = liters per minute;
MAC = monitored anesthesia care;
MC = manually controlled;
min = minutes;
mg = milligrams;
ml · h-1  = millilitres per hour;
mcg = micrograms;
mg · ml-1 = micrograms per millilitre;
mg · kg-1 · h-1 = micrograms per kilogram per minute;
MOAA/S = Modified Observer’s Assessment of Alertness and Sedation;
mmHg = millimetre of mercury;
n = number of patients;
NAPS = nurse administered propofol sedation;
9NIBP = non-invasive blood pressure;
PCS = patient-controlled sedation;
PI = propofol infusion;
PPC = propofol plasma concentrations;
PMS = patient-maintained sedation;
RASS = Richmond Agitation-Sedation Scale;
RR = respiratory rate;
SD = standard deviation;
SIVA = Society of Intravenous Anesthesia;
SpO2 = peripheral oxygen saturation;
SRAE = sedation related adverse events;
TCI = target-controlled infusion;
US = United States; 
VAS = visual analogue scale;
VRS = verbal rating scale;
WMA = World Medical Association.
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4 introduction
Endoscopic retrograde cholangiopancreatography (ERCP) is a complex 
gastrointestinal endoscopic procedure that involves cannulation and radiographic 
imaging of the biliary tree and pancreatic duct and is used in the diagnosis and 
treatment of a wide spectrum of biliary and pancreatic disorders. The procedure 
is started with the insertion of duodenoscope and filling the stomach and small 
intestinum with air or carbon dioxide; thereafter the duodenal papilla is accessed for 
cannulation. At this stage and, if needed, during consequent procedure, glucagon is 
often administered intravenously in order to inhibit duodenal motility. After papilla 
cannulation contrast media is injected through the catheter under fluoroscopic 
monitoring for visualization of biliary or pancreatic duct system. Sphincterotomy of 
the bile or pancreatic duct might be performed in order to facilitate stent placement 
or removing of the stones. Existing biliar/pancreatic stricture may be dilated with 
the use of hydrostatic wire-guided balloon. Dilation of pancreatic duct is often very 
painful while sphincterotomy and biliar dilations are significantly less painful. It 
is believed that other stages of ERCP do not produce marked painful stimulation. 
ERCP duration differs markedly (range 10-120 minutes) depending on skills of 
endoscopist and complexity of procedure. In most difficult cases, such as altered 
gastrointestinal anatomy, duration of ERCP usually exceeds 90 minutes (Osoegawa 
T et al. 2012).    
The diagnostic and therapeutic utility of ERCP has been demonstrated in the 
diagnosis and management of choledocholithiasis, primary sclerosing cholangitis, 
chronic pancreatitis, biliary and pancreatic neoplasm, and biliary perioperative 
complications. ERCP has been practiced for over 30 years being firstly described 
in 1968. In excess of several 100.000 of this procedures are performed annually 
worldwide with possible demand only for China as much as 1 million annually 
(Liao Z et al. 2013).  
ERCP has a complication rate of 5 % -10 % and mortality rate of 0.1 % - 1 
% (Williams E et al. 2007). Reported complication rates vary widely because of 
differences in definitions of complications and patient population. Complications 
include acute pancreatitis, hemorrhage, perforation, infection (cholangitis, 
cholecystitis, endocarditis), cardiopulmonary and miscellaneous (Anderson MA 
et al. 2012). Pancreatitis is the most common of serious ERCP complications. 
Often occurred transient increase in serum pancreatic enzymes does not constitute 
pancreatitis. The incidence of post-ERCP pancreatitis ranges widely (1.6 -15.7 %) 
depending on patient selection. The rate of post-ERCP hemorrhage is 1-1.5 % 
and is primarily related to sphincterotomy. Hemorrhage may be immediate or 
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delayed up to 2 weeks. Most ERCP-associated bleeding is intraluminal and mild 
in origin, also intraductal bleeding and hematomas (hepatic, splenic, and intra-
abdominal) can occur. Perforation complicates 0.1-0.6 % of ERCPs procedures. 
Malignancy and precut access were associated with an increased risk of perforation 
(Williams E et al. 2007). The incidence of post-ERCP cholangitis does not exceed 
1 %. Cholecystitis complicates approximately 0.2 - 0.5 % of ERCPs. Significant 
cardiopulmonary complications (cardiac arrhythmia, hypoxemia, aspiration) 
occur in 1 % of ERCP patients with associated mortality 0.07 % (Andriulli A et al. 
2007). In the study of Fisher 8 % of patients older than 65 years of age sustained 
myocardial injury with most injury occurred during prolonged procedures (Fisher 
L et al. 2006). Cardiopulmonary complications may also arise from medications 
used for sedation and analgesia. The overall mortality rate after diagnostic ERCP 
is 0.2 % being twice as high (0.4 %-0.5 %) after therapeutic ERCP. A wide variety 
of miscellaneous complications may occur: ileus, hepatic abscess, pneumothorax/
pneumomediastinum, perforation of colonic diverticulum, duodenal hematoma, 
portal venous air, impaction of therapeutic devices, pseudocyst infection, stent 
migration, stent occlusion, liver abscess, and acute cholecystitis.
Undoubtedly, ERCP is a one of the most complex and time-demanding 
procedures among gastrointestinal endoscopies. Patients are required to stay 
completely still during uncomfortable and sometimes painful procedure because 
any inappropriate movement can affect the success of ERCP. For better toleration 
of ERCP patients receive sedatives and/or analgesics. Recently the use of sedation 
or general anesthesia was reported in 100 % of ERCP at least in Spain and Greece 
(Triantafillidis J et al. 2013). Adequate sedation during ERCP is indispensable 
because insufficient sedation may result in patient discomfort, adverse physiological 
responses or even injury. On the other hand, excessive sedation may cause dangerous 
cardio-respiratory depression and loss of protective airway reflexes. Sedation with 
propofol during ERCP is superior to traditionally used benzodiazepines mainly 
because of significantly faster recovery (Garewal D et al. 2012, Bo LL et al. 2011). 
However, such important issues as the targeted level of sedation, the appropriate 
use and method of administration of sedative drugs during ERCP are unanswered 
and providing of adequate sedation is based mostly on clinical experience. 
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5 review of the literature 
5.1 Sedation and analgeSia in gaStrointeStinal   
 endoScopy
A wide range of gastrointestinal (GI) endoscopy procedures are carried out in an 
endoscopy unit. Procedures range from minimally invasive (colonoscopy) to much 
more invasive and complex such as ERCP and endoscopic submucosal resection. 
Sedation and analgesia are integral parts of each GI endoscopy procedure (Cohen 
LB et al 2010). Sedation is defined as a drug-induced depression of the level of 
coconsciousness. American Society of Anesthesiologists has defined three levels of 
sedation with continuity to general anesthesia (Table I). 
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Table I Continuum of depth of sedation: Definition of general anesthesia and levels of sedation/analgesia 
Functions Minimal seda-
tion(anxiolysis) 
Moderate sedation 
(analgesia, con-
scious sedation) 
Deep sedation 
(analgesia) 
General anesthesia 
Responsiveness normal verbal 
response  
purpose response to 
speech or physical 
stimuli 
purpose response to 
repeated or painful 
stimuli 
no response to pain 
Spontaneous 
ventilation 
unaffected unaffected may be inadequate inadequate 
Airway  unaffected unaffected intervention may be 
needed 
interventions needed  
(mask, intubation, me-
chanical ventilatory sup-
port) 
Cardiovascular 
functions 
unaffected usually unaffected  usually unaffected may be impaired (hypoten-
sion, bradycardia) 
 
At the level of minimal and moderate sedation patients are able to make purposeful response to verbal stimu-
lation and as a rule, have unaffected respiration and hemodynamics. In contrast, deeply sedated patients are 
unable to communicate verbally and respond only to painful stimuli. Also spontaneous respiration and hemo-
dynamics can be affected more frequently at the level of deep sedation. Airway and hemodynamic support 
may be required in deep sedation. Sedation represents a continuum - the cascade of events with progressive 
alteration in level of responsiveness (ASA practice guideline 2002, Green and Mason 2010). The transition 
from one sedation level to another may occur with the currently used sedation techniques. It can be difficult 
to control the required level of sedation because of patient’s individual response to sedatives and to nocicep-
tive stimuli. Therefore, health professional involved in the administration of sedation should possess the skills 
At the level of minimal and moderate sedation patients are able to make 
purposeful response to verbal stimulation and as a rule, have unaffected respiration 
and hemodynamics. In contrast, deeply sedated patients are unable to communicate 
verbally and respond only to ainful stimuli. Also spontaneous respiration a d 
hemodynamics can be affected more frequently at the level of deep sedation. 
Airway and hemodynamic support may be required in deep sedation. Sedation 
rep sents a continuum - the cascade of events with progressive alteration in level 
of responsiveness (ASA practice guideline 2002, Green and Mason 2010). The 
transition from one sedation level to another may occur with the currently used 
sedation techniques. I  can be difficult to ontrol th  required level of sed tion 
because of patient’s individual response to sedatives and to nociceptive stimuli. 
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Therefore, health professional involved in the administration of sedation should 
possess the skills to recognize sedation related problems and rescue a patient from 
reached deeper sedation level than it was initially intended.    
The main purposes of sedation and analgesia during gastrointestinal endoscopy 
are to relieve patient’s discomfort, pain and anxiety, to reduce memory of unpleasant 
event and to facilitate procedural performance. Mild to moderate sedation is 
commonly given by the endoscopist but an anesthesia team is usually required for 
deep sedation (Riphaus A et al. 2009).
5.1.1 BenzodiazepineS and opioidS
In Europe, US, Canada and Japan majority of GI endoscopies typically performed 
under moderate sedation (ASA, practice guideline 2002) with benzodiazepines 
alone or in combination with an opioid. Benzodiazepines are the most often used 
sedation agents by endoscopists of Italy, Greece and Switzerland (Fanti L et al. 2011). 
Benzodiazepines do not provide analgesia and for this reason they are commonly 
co-administered with opioids. In the recent nationwide survey from Germany the use 
of benzodiazepine and opioid combination was reported in 35 % of GI endoscopies 
(Riphaus A et al. 2010). Serious adverse effects of benzodiazepines are rare: dose-
dependent respiratory depression may occur especially in patients with underlying 
respiratory disease and sedated with combination of benzodiazepines and opioid 
(Cohen LB et al. 2007). Flumazenil and naloxone are available antagonists for 
benzodiazepines and opioids, respectively. 
Midazolam and diazepam are the most commonly used benzodiazepines with 
comparable efficacy of sedation (Faigel DO et al. 2002). Midazolam has been 
reported more suitable than diazepam because of better amnesic properties, 
shorter duration and faster onset of action (Ginsberg GG et al. 1992, Macken E et 
al. 1998, Waring J et al. 2003). A double-blind placebo-controlled evaluation of 
oral midazolam for premedication of patients undergoing upper endoscopy showed 
a high efficacy in reduction of anxiety and improving procedural tolerance with a 
good safety profile (Mui LM et al. 2005). 
Comparison of alfentanil/midazolam with midazolam alone for upper GI 
endoscopy showed improvement in procedural performance and a shorter recovery 
time in patients received combination of midazolam and alfentanil (Milligan KR 
et al. 1988). Comparison of midazolam/meperidine with midazolam alone during 
colonoscopy showed significantly less pain and a higher rate of willingness to 
repeat the intervention without difference in SRAE in patients received midazolam/
meperidine (Radaelli F et al. 2003).
For many years meperidine was the primary choice in GI endoscopy (Keeffe 
EB et al. 1990). During the last decade fentanyl, alfentanil and remifentanil have 
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appeared as good alternatives for GI sedation in a number of studies (Cohen LB 
et al. 2004, el-Bitar N and Sfeir S 2006, Ishido S et al. 1992, Fanti L et al. 2009, 
Fanti L et al. 2013, Liu S et al. 2009, Mandel J et al. 2008, Mandel J et al. 2010, 
Akcaboy ZN et al. 2006).
5.1.2 propofol
Propofol is an intravenous anesthetic with a dose-related sedative and hypnotic 
properties but only minimal analgesic effect (Smith et al. 1994). The drug has a 
rapid onset of action, is shorting acting and rapidly metabolized by the liver (Table 
III). Very rapid onset and short duration of action make it a suitable sedative for 
gastrointestinal endoscopy (Patterson KW et al. 1991, Carlsson U et al. 1995, Koshy 
G et al. 2000, Reimann FM et al. 2000, Sipe BW et al. 2002, Weston B.R. et al. 
2003, Faga E et al. 2012). 
Compared with benzodiazepines, propofol presents similar rate of adverse effects 
(Kongkam P et al. 2008, Riphaus A et al. 2005, Vargo JJ et al. 2002, Wehrmann 
T and Riphaus A 2008, Jung M et al. 2000, Schilling D et al. 2009, Singh H et al. 
2008, McQuaid KR and Laine L 2008, Qadeer MA et al. 2005), but provides higher 
patient satisfaction (Jung M et al. 2000, McQuaid KR and Laine L 2008, Dewitt 
J et al. 2008),and decreases both sedation induction and recovery time (McQuaid 
KR 2008, Mandel J et al. 2008, Singh H et al. 2008, Ulmer BJ et al. 2003, Vargo 
J et al. 2002, Riphaus A et al. 2006). Propofol sedation may increase the quality 
of endoscopic examination (Jung M et al. 2000, Meining A et al. 2007).
Propofol can be administered in intermittent boluses or continuous infusion 
(Fanti L 2004 et al., Kongkam P et al. 2008, Thaharavanich R et al. 2011). Propofol 
bolus administration is well documented during GI endoscopy (Hsieh Y et al. 2009, 
Liu S et al. 2009, Paspatis G et al. 2008, Poon C et al. 2007, Riphaus A et al. 2005, 
Rex D et al. 2009, Seifert H et al. 2000, Sipe B et al. 2007, Zippi M et al. 2008, 
Heuss L et al. 2012, Wehrmann T et al. 1999).
However, only few studies exists about the use of continuous propofol infusion 
in endoscopy, mainly with implementation of target-controlled infusion (TCI) 
(Fanti L et al. 2004, Fanti L et al. 2007, Kongkam P et al. 2008, Thaharavanich 
R et al. 2011, Kulling D et al. 2004, Hsu W et al. 2013). The device for propofol 
infusion (infusion pump) can be controlled manually (manually controlled infusion, 
MC) or microprocessor controlled (target-controlled infusion, TCI). In MC mode 
sedation provider makes each change to the infusion rate in attempt to maintain 
the desired level of sedation. In TCI mode all necessary changes in infusion rate are 
controlled by microprocessor to reach and maintain a desirable propofol plasma 
(CP) or effect-site (CE) concentration adjusted by sedation provider. Usually TCI 
administration protocol consider patient’s age, gender and weight to predict 
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individual pharmacokinetic changes in propofol CP or CE and thus giving possibility 
for individualized dosing of sedatives. 
Several pharmacokinetic models have been created for TCI of propofol (Marsh 
B et al. 1991, Schnider et al. 1999, Gepts E et al. 1987). The pharmacokinetic model 
described by Schnider uses CE steering that allows achievement of desired sedation 
level more rapidly than with CP steering (Leslie K et al. 2008).
In the randomized comparison between propofol bolus administration and 
continuous infusion for ERCP and EUS (n=100) both administration methods 
allowed identically good sedation with similar efficacy and patient safety. However, 
continuous infusion was associated with delayed recovery and more frequent 
hypotension (Riphaus A et al. 2012). The intermittent bolus administration of 
propofol is a current standard practice of propofol administration in GI endoscopy 
(Riphaus A et al. 2008, Vargo J et al. 2009, Heuss et al. 2012).
The use of propofol for sedation is recommended only for persons with 
appropriate training in administration of general anesthesia and not involved in the 
conduction of diagnostic or surgical procedure (Perel A 2011). Specific antagonists 
of propofol are not available.
5.1.3 other medicationS
Ketamine
Ketamine is N-Methyl-D-aspartate receptor antagonist and produce dissociation 
between limbic and cortical systems with minimal respiratory and cardiovascular 
depressive effects (White P et al. 1982). Ketamine alone or in combination with other 
sedatives has been evaluated for sedation mainly in pediatric patients. In difficult-
to-sedate adult patients ketamine provided deeper sedation and faster recovery than 
additional doses of meperidine and diazepam in patients who were inadequately 
sedated with the last mentioned combination during ERCP and EUS (Varadarajulu 
S et al. 2007). Fabbri L compared propofol-ketamine-remifentanil sedation with 
propofol-remifentanil in 322 patients during ERCP procedures. Lighter sedation 
levels, better analgesia, lower incidence of post-procedural nausea and vomiting 
and shorter discharge times were reported in patients received propofol-ketamine-
remifentanil (Fabbri L et al. 2012). A Study of Rosing showed improvement of 
sedation success rate (100 % vs. 85 %) in patients received midazolam/ketamine 
for colonoscopy compared to midazolam alone (Rosing C et al. 1991). Sedation 
induction with combination of ketamine, midazolam, pentazocine and propofol 
resulted in improved patient tolerance compared with propofol alone during ERCP 
(Ong WC et al. 2007).
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Dexmedetomidine
Dexmedetomidine is a highly selective α-2 adrenoreceptor agonist with sedative 
and analgesic properties and without any significant influence on spontaneous 
respiration. Dexmedetomidine has approval of Food and Drug Administration for 
procedural sedation (Shukry M and Miller J 2010). Dexmedetomidine results in 
reduction of heart rate and systemic sympathetic tone without changes in baroreflex 
sensitivity (Hogue C et al. 2002). The role of dexmedetomidine sedation for GI 
endoscopy is not entirely established. The studies about dexmedetomidine suitability 
for GI endoscopy have controversial results. A trial investigating dexmedetomidine 
suitability for colonoscopy (Jalowiecki P et al. 2005) needed to be terminated 
because of adverse events (bradycardia and hypotension). In the study of Muller 
dexmedetomidine alone was less effective than propofol-fentanyl during ERCP 
and produced greater hemodynamic instability and prolonged recovery (Muller S 
et al. 2008). The studies evaluated dexmedetomidine use for upper GI endoscopies 
showed good results (Hashiguchi K et al. 2008, Takimoto K et al. 2011, Demiraran 
Y et al. 2007). 
Nitrous oxide 
Nitrous oxide is an odorless gas with analgesic properties and in allowed 
concentrations acts as a weak anesthetic. Nitrous oxide has been studied only 
during colonoscopy. Patient-controlled nitrous oxide inhalation showed better 
cardiorespiratory stability and faster recovery than midazolam/pethidine during 
colonoscopy (Saunders BP et al. 1994). In another study during colonoscopy nitrous 
oxide was less effective and produced worse intraprocedural analgesia and patient 
satisfaction than midazolam/meperidine (Forbes GM and Collins BJ 2000). In 
a study of Maslekar patient-controlled nitrous oxide inhalation (Entonox - 50 % 
nitrous oxide and 50 % oxygen) was compared with patient-maintained target-
controlled infusion of propofol during colonoscopy in terms of analgesic efficacy, 
depth of sedation, manoeuvrability and patient and endoscopist satisfaction. Nitrous 
oxide appeared to be of equal efficacy with propofol patient-maintained target-
controlled infusion during colonoscopy (Maslekar S et al. 2011). Comparison of 
nitrous oxide with midazolam-fentanyl sedation for colonoscopy showed better 
efficacy of nitrous oxide because of better pain relief and faster recovery (Maslekar 
S et al. 2009). The use of nitrous oxide as monosedation in GI endoscopy is not 
supported by sedation guidelines (Riphaus A et al. 2008). 
17
5.1.4 Sedation related adverSe eventS
Although strict definition of sedation related adverse events (SRAE) in the 
existing literature lacking, in the majority of studies SRAE were defined as 
adverse cardiovascular or respiratory events during sedation. Despite of defined 
and published threshold at which an adverse event during endoscopy becomes a 
significant (Cotton PB et al. 2010), the designation of cardiovascular or respiratory 
events during sedation varies markedly in the reported studies. For example in the 
study of Cote´ reporting  the incidence of sedation-related complications during 
advanced Endoscopy under propofol sedation (Coté G et al. 2010) SRAE included 
airway modifications (chin lift, nasal airway, bag-mask ventilation, endotracheal 
intubation), hypoxemia (SpO2 below 90 %), hypotension requiring vasopressors, 
and early procedure termination. In the retrospective study of Agostoni summarizing 
8-year experience of monitored anesthesia care for GI endoscopy SRAE were defined 
as occurrences that warranted intervention and were classified as hypotension, 
desaturation, bradycardia, hypertension, arrhythmia, aspiration, respiratory 
depression, vomiting, cardiac arrest, respiratory arrest, angina, hypoglycemia, and/
or allergic reaction (Agostoni M et al. 2011). 
The most recent consensus on definition of SRAE was made by the International 
Sedation Task Force (ISTF) of the World Society of Intravenous Anaesthesia (World 
SIVA). Based on standardised definitions of SRAE the Adverse sedation event-
reporting tool that is potentially relevant to all specialties and providers was created 
by ISTF. ISTF propose recognition of sentinel, moderate, minor and minimal SRAE 
(Mason K et al. 2012).
Few studies have compared traditional sedation (benzodiazepine and opioid 
combination) with propofol sedation during ERCP (Kongham P et al. 2008, 
Riphaus A et al. 2005, Vargo JJ et al. 2002, Wehrmann T et al. 1999, Jung M et 
al. 2000, Schilling et al. 2009). In the study of Kongham P 2008 reporting 134 
ERCP patients sedated with gastroenterologist administered propofol infusion (PI) 
(n=67) or meperidine-midazolam (MM) boluses (n=67) SpO2 decreased below 90 
% in 20 % of patients in PI and in 30 % of patients in MM groups. Hypotension 
occurred in 10 % of patients in both groups and bradycardia in 3 % in PI group 
and in 10 % of patients in MM group. Other studies comparing propofol sedation 
with traditional sedation during ERCP (Riphaus A et al.2005, Vargo JJ et al. 
2002, Wehrmann T et al. 1999, Jung M et al. 2000) reported incidence of SRAE 
comparable with the study of Kongham. A Cochrane review concluded that there was 
no difference between propofol and traditional sedation regarding adverse events. 
Berzin T in prospective assessment of SRAE during 528 consecutive ERCP under 
AAS or GA reported the total incidence of SRAE 21 %: SpO2 below 85 % occurred 
in 13 %, unplanned endotracheal intubation in 3 %, procedure termination in 0.2 
%, hypotension in 7 %, arrhythmias in 4 % and pulmonary aspiration in 0.4 % of 
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patients (Berzin TM et al. 2011). In a retrospective study with 2207 ERCPs under 
monitored anesthesia care (Agostoni M et al. 2011) a procedural complication rate 
of 5.3 % and an incidence of SRAE of 0.1-3 % was found. Interestingly, in this 
study hypotension was reported more frequent and desaturation secondly frequent 
SRAE (Agostoni M et al. 2011). As a rule, monitored anesthesia care during ERCP 
is safe and regardless of high incidence (20-30 %) of minor SRAE major sedation 
related problems occurs relatively rare (5-10 %). In a retrospective data published 
by Wehrmann consisting of 9547 patients received propofol sedation (3151 patients 
propofol alone and 6396 patients combination of propofol and midazolam) for 
interventional upper endoscopy (EGD, n = 5374, ERCP, n = 3937, EUS, n = 236) 
severe SRAE, leading to interruption of the procedure were reported in 1.4 % of 
patients. Bag-mask ventilation was needed in 0.4 % and endotracheal intubation in 
0.09 % of patients respectively. Sedation related mortality and ICU admission were 
reported in 0.03 % and 0.3 % of patients respectively. Emergency interventions 
and a higher propofol dose were assessed as an independent risk factors for 
cardiorespiratory complications (Wehrmann T and Riphaus A 2008).
Jowell P et al (1996) compared traditional sedation (n=31) with PCS using 
meperidine-midazolam mixture (n=31) during ERCP and reported that not 
SRAE occurred in the PCS group (Jowell P et al. 1996). In the study of Gillham 
about patient-maintained propofol sedation during ERCP (n=20) SRAE did not 
occurred but 20 % of sedations failed (Gillham M et al. 2001). In the Study of 
Mandel comparing midazolam-fentanyl PCS (n=24) with propofol–remifentanil 
PCS (n=25) during colonoscopy SRAE were reported in 12 % of patients (Mandel J 
et al. 2008). Comparison of propofol-remifentanil PCS with propofol-remifentanil 
AAS during colonoscopy (Mandel J et al. 2010) reveal significant difference between 
study groups in the incidence of respiratory events (0 % in PCS vs. 20 % in AAS) 
but this study is potential for bias with AAS.
5.2 patient SatiSfaction 
The most important factor affecting patient satisfaction is the degree of discomfort/
pain experienced by patient. Maslekar studied prospectively patient satisfaction with 
flexible sigmoidoscopy performed in 503 patients by medical doctors, nurses and 
non-medical endoscopists (non healthcare professionals) and tried to determine 
factors influencing patient satisfaction. No differences were detected between 
performing parties in patient rating for overall satisfaction. Higher pre-procedure 
anxiety, history of pelvic operations and higher pain scores were associated with 
adverse patient satisfaction (Maslekar S et al. 2010). In the study investigated 
influence of analgesia during flexible sigmoidoscopy patient satisfaction was 
significantly higher with analgesia than without (Basu S et al. 2004). In consequence, 
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reducing of periprocedural anxiety (sedation) and analgesia have an important role 
in the overall patient satisfaction. Gastroscopy under sedation is preferred by 40 % 
– 60 % of patients (Olithselvan A et al. 2004). Anxious female and young patients 
especially benefit from sedation (Rex et al. 1999, Campo R et al. 1999). The positive 
influence of sedation on acceptance of GI endoscopies was established in other 
studies (Hedenbro et al. 1991, Kinoshita Y et al. 1991, Yuno K et al. 1996, Ristikankare 
M et al. 1999, Marriott P et al. 2004). However, under benzodiazepine sedation 
patients may have discomfort or pain that the endoscopist may not notice (Rex D 
et al. 1999, Walmsley R and Montgomery S 1998). In comparisons of propofol with 
traditional sedatives during GI endoscopy propofol provided higher post-procedural 
patient satisfaction (Roseveare C et al. 1998, Ulmer B et al. 2003, Vargo J et al. 2002, 
Sipe et al. 2002, Weston B et al. 2003). In the study reported patient satisfaction 
under AAS during ERCP 10-point VAS sedation satisfaction score was recorded 
for 461procedures. The overall mean sedation satisfaction score was somewhat 
higher for patients under sedation compared with patients receiving GA (9.3 vs. 
8.4). Among outpatients (n=238) the mean satisfaction score was 9.9 and only 6 
% of patients reported some memory of the ERCP procedure.
5.3 patient-controlled Sedation 
PCS is a delivery of sedative medications during unpleasant diagnostic and 
therapeutic procedures that is initiated and controlled by the patient (Atkins J and 
Mandel J 2008). PCS is originated from patient-controlled analgesia (PCA). PCS 
enables the patient to control the amount of sedatives and the timing of delivery, 
and thus offers individual sedation for each patient and procedure. First experience 
of PCS clinical use was reported in dentistry (Rudkin G et al. 1991, Osborn G et 
al. 1991). 
Patient-maintained sedation (PMS) is a modification of PCS that describes 
sedation which is initiated by anesthesia provider and maintained by the patient 
at the level desired by the patient. In the studies describing PMS sedatives were 
mostly administered with the use of TCI systems (Gillham M et al. 2001, Campbell 
L et al. 2004, Fanti L et al. 2007, Stonell C et al. 2006). There applicability of PCS 
and PMS has been reported in a variety of invasive procedures (Table II)
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Table II Applications of PCS and PMS 
CONDITION REFERENCE 
ERCP Jowell P 1996, Gillham M2001 
colonoscopy Mandel J 2008, Mandel J 2010,Crepeau T 2005, Roseveare 
C 1998, Bright E 2003, Lee D 2002, Stonell C 2006,Külling 
D 2001,Heuss L 2004,Ng J-M 2001, Heiman D 1998, Lee D 
2004, Campbell L 2004 
EUS Agostoni M 2007  
cataract surgery(supplementation to local anesthe-
sia) 
Janzen P 1999, Yun M 2008,Morley H 2002 
dental treatment Oei-Lim V 1998, Rudkin G 1991, Osborn G 1991, Chapman 
R 2006,Rudkin G 1992, Leitch J 2004, Rodrigo M 2003 
fiberoptic bronchoscopy Hwang J 2005, 
shockwave lithotripsy Alhashemi J 2002, Joo H 2001 
dressing changes  Coimbra C 2003,Nilsson A 2008 
emergency 
room surgical procedures 
Bell A 2010 
gynecology and urology Dell R 1998, Nilsson A 2012, Tripathi M 2009, Cook L 
1993 
neurosurgery, orthopedics and general surgery 
(adjuvant to local or regional anesthesia) 
Irwin M 1997, Ganapathy S 1997, Herrick I 1997, Joo J 
2012, Wahlen B 2008 
intensive care unit Chlan L 2010 
 
 
Sedatives used in PCS include midazolam (Jowell P et al. 1996, Rudkin G et al. 1992), propofol, or combina-
tion of both with different opioids (meperidine, fentanyl, remifentanil, alfentanil) (Agostoni M et al. 2007, 
Joo H et al. 2001, Dell R and Cloote A 1998, Hwang J et al. 2005, Nilsson A et al. 2012, Crepeau T et al. 
2005 ). Pharmacokinetics of drugs used for PCS is shown in Table III. 
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Table III Pharmacokinetics of drugs used for PCS 
Drug onset of action duration of action t1/2 
midazolam 1-5 min 1-3 h 1,5 – 2.5h 
propofol 30-60 sec 3-10 min 30-60 min 
fentanyl 30-60 sec 30-60 min 1,5 – 3h 
alfentanil 30 sec 15-20 min 1,5 – 2,5h 
remifentanil 30 sec 5-10 min 3-10 min 
meperidine 1-3 min 2-3 h 4-6 h 
PCS-patient-controlled sedation, t1/2-biological half-life, h- hour, min-minute, sec-seconds 
 
Comparison between midazolam and propofol for PCS (Rudkin G et al. 1992, Mandel J et al. 2008) showed a 
better recovery profile after propofol PCS with comparable satisfaction with sedation and incidence of SRAE. 
Alfentanil and remifentanil were not compared previously in sedative mixture for PCS. 
In the majority of comparisons between PCS and anesthesia provider administered sedation, PCS leads to 
reduction of total dose of sedatives and faster recovery (Crepeau T et al. 2005, Roseveare C et al. 1998). In 
the study of Heuss comparing PCS with nurse administered propofol sedation during colonoscopy consump-
tion of sedatives was somewhat higher in the PCS group, but significant difference between study groups was 
not achieved and procedures were longer in the PCS group (Heuss LT et al. 2004). PCS has been extensively 
studied during colonoscopy with good results (Table IV). PCS was reported to be successfully used without 
supervision of anesthesiologist (Table IV).  
 
 
 
 
 
 
 
 
Comparison between midazolam and propofol for PCS (Rudkin G et al. 1992, 
Mandel J et al. 2008) showed a better recovery profile after propofol PCS with 
comparable satisfaction with sedation and incidence of SRAE. Alfentanil and 
remifentanil were not compared previously in sedative mixture for PCS.
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In the majority of comparisons between PCS and anesthesia provider 
administered sedation, PCS leads to reduction of total dose of sedatives and faster 
recovery (Crepeau T et al. 2005, Roseveare C et al. 1998). In the study of Heuss 
comparing PCS with nurse administered propofol sedation during colonoscopy 
consumption of sedatives was somewhat higher in the PCS group, but significant 
difference between study groups was not achieved and procedures were longer in 
the PCS group (Heuss LT et al. 2004). PCS has been extensively studied during 
colonoscopy with good results (Table IV). PCS was reported to be successfully used 
without supervision of anesthesiologist (Table IV). 
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Table IV Studies about PCS for colonoscopy 
Study reference drugs n of patients success rate ASA class SRAE presence of 
anesthesiologist 
Lee D 2004 propofol/ alfentanil 500 98 % I-III 8,6 % No 
Roseveare C 1998 propofol/ alfentanil 33 100 % I-III 0 % Yes 
Ng J-M 2001 propofol 44 100 % I-II 0 % Yes 
Lee D 2002 propofol/ alfentanil 50 (>65y) n/a II-IV 4 % No 
Kulling D 2001 propofol/ alfentanil 50 100 % I-II 4 % No 
Heuss L 2004 propofol 36 100 % I-III 3 % No 
Crepeau T 2005 propofol 72 97 % I-III 9 % Yes 
Mandel J 2008 propofol/ remifentanil  
midazolam/ fentanyl 
25(PR) 
25(MF) 
100 % I-III 4%(PR) 
0%(MF) 
Yes 
Mandel J 2010 propofol/ remifentanil 25 100 % I-II 0 % Yes 
Heiman D 1998 propofol (n=8) 
propofol/ alfentanil 
(n=12)  
20 100 % n/a 0 % n/a 
Bright E 2003 propofol/ alfentanil 33 100 % n/a 0 % No 
n-number of patients, ASA-American Society of Anesthesiologists, SRAE-sedation related adverse events, PR-
propofol/remifentanil, MF-midazolam/fentanyl, y-years, n/a-not available 
 
However, only 2 studies exist describing the use of PMS but not about PCS for ERCP (Jowell P 1996 et al., 
Gillham M et al.2001). In the study of Jowell nurse assistant administered sedation with midazo-
lam/meperidine (n=35) was randomly compared with nurse initiated patient maintained midazo-
lam/meperidine (n=35) sedation during ERCP. All ERCP were successfully completed. PMS failed in 3/35 
patients. Patient satisfaction and incidence of SRAE did not differ between the groups (Jowell P et al. 1996). 
In a pilot study of Gillham PMS with propofol TCI described in 20 ERCP patients. PMS failed in 4/20 pa-
tients. Patient and endoscopist satisfaction was high and serious SRAE did not occur (Gillham M et al. 2001). 
 
5.4. Assessment of sedation 
Monitoring of sedation levels during GI sedation is recommended in the recent sedation guideline (Cohen L 
et al. 2010). However, assessment of sedation level remains to be an elusive aim. A number of sedation scales 
which measure the patient’s responsiveness to verbal, physical or painful stimuli (Ramsay M et al. 1974, 
Manyam S et al. 2007, Gillham M et al. 2001, Ely E et al. 2003, Chernic D et al. 1990) were developed pre-
dominantly for the measurement of unconsciousness. Although sedation scales often used in the assessment 
However, only 2 studies exist describing the use of PMS but not about PCS for 
ERCP (Jowell P 1996 et al., Gillham M et al.2001). In the tudy of Jowell nurse 
assistant administered sedation with midazolam/meperidine (n=35) was randomly 
compared with nurse initiated patient maintained midazolam/meperidine (n=35) 
sedat o  during ERCP. All ERCP were successfully completed. PMS failed in 3/35 
patients. Patient satisfaction and incidence of SRAE did not differ between the 
groups (Jowell P et al. 1996). In a pilot study of Gillham PMS with propofol TCI 
described in 20 ERCP patients. PMS faile  in 4/20 patients. atient and endoscopist 
satisfaction was high and serious SRAE did not occur (Gillham M et al. 2001).
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5.4 aSSeSSment of Sedation
Monitoring of sedation levels during GI sedation is recommended in the recent 
sedation guideline (Cohen L et al. 2010). However, assessment of sedation level 
remains to be an elusive aim. A number of sedation scales which measure the 
patient’s responsiveness to verbal, physical or painful stimuli (Ramsay M et al. 
1974, Manyam S et al. 2007, Gillham M et al. 2001, Ely E et al. 2003, Chernic D et 
al. 1990) were developed predominantly for the measurement of unconsciousness. 
Although sedation scales often used in the assessment of procedural sedation, none 
of them has been validated in GI sedation. For example with the aid of MOAA/S scale 
differentiation between deep sedation and general anesthesia may be cumbersome 
because of the lack of sensitivity (Bailey P and Zuccaro G 2006). 
Level of sedation may be quantified by processed electroencephalography. This 
type of monitors includes bispectral index and state entropy. The results of studies 
about utility of bispectral index and state entropy monitoring in sedated patients 
are controversial (Mahon P et al. 2008, Drake L et al. 2006, Sasaki T et al. 2012, 
von Delius V et al. 2012) and do not support its routine use in GI sedation. Finally, 
auditory evoked potentials have been investigated in the assessment of sedation in 
volunteers with promising effects (Haenggi M et al. 2004) but studies are lacking 
in GI sedation.
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6 aiMs of the study
The aim of this thesis was to examine the suitability of PCS for the sedation of 
patients undergoing ERCP in terms of propofol consumption, sedation levels, 
sedation related adverse events, patient satisfaction with sedation, the ease of ERCP 
performance, and recovery profile.  The specific aims of the studies I-IV were:
1) To compare PCS with anesthesiologist administered propofol sedation 
during ERCP using either a constant infusion or TCI (I, III)
2) To compare remifentanil and alfentanil in PCS during ERCP (II)
4) To evaluate the suitability of dexmedetomidine in addition to PCS for 
sedation of alcoholics during ERCP (IV)
4) To assess the success rate of PCS during ERCP (I-IV)
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7 Materials and Methods
7.1 patientS
The thesis population consisted of 293 patients undergoing elective ERCP in the 
Endoscopy unit at Helsinki University Central Hospital from January 2009 to 
January 2011 (studies I-IV). Demographics of the study patients are shown in the 
Table 1. Among study patients 101(35 %) were females and 192(65 %) males. 201 (69 
%) patients belonged to ASA class I and II and 92(31 %) patients to ASA class III. 
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7. Materials and methods 
7.1. Patients. 
The thesis population consisted of 293 patients undergoing elective ERCP in the Endoscopy unit at Helsinki 
University Central Hospital from January 2009 to January 2011 (studies I-IV). Demographics of the study 
patients are shown in the Table 1. Among study patients 101(35 %) were females and 192(65 %) males. 201 
(69 %) patients belonged to ASA class I and II and 92(31 %) patients to ASA class III.  
Table 1  Demographic data of the study patients 
Demographics and co-morbidities 
 
I II III IV 
patients, n 80 81 82 50 
Age (mean, (SD) 51(12) 48(12) 47(12) 50(8) 
Gender (M/F)  (n) 51/29 46/35 53/29 42/8 
BMI  (mean, (SD) 25(5) 25(5) 23(4) 23(4) 
ASA class  1/2/3 (n) 13/37/30 25/32/24 28/31/23 7/28/15 
Cardiovascular disease % (n) 28(22) 27(22) 26(21) 22(11) 
Diabetes % (n) 20(16) 15(12) 16(13) 14(7) 
Chronic lung disease % (n) 3(2) 10(8) 5(4) 6(3) 
n-number of patients, SD-standard deviation, M-male, F-female, BMI-body mass index, ASA- 
American Society of Anesthesiology 
 
7.2. Study designs 
All studies I-IV were prospective randomized controlled trials with parallel assignment (Table 2). Sealed 
non-transparent envelopes were used for randomization in studies I-IV. Computer-generated random numbers 
were used in the study IV and letters in the studies I-III. Informed content was obtained on the day of proce-
dure thereafter patients were allocated to the study arm. 
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Table 2  Design of the studies 
 I II III IV 
Date of enrolment Jan-Apr 2009 June-Sep 2009 Mar-Nov 2010 Mar2010-Jan-11 
Number of Arms 2 3 2 2 
Masking open label double-blind open label double-blind 
Inclusion Criteria 
 
elective ERCP-
patients 
age 18-70 years 
elective ERCP-
patients 
age 18-70 years 
elective ERCP-
patients 
age 18-75 years 
elective ERCP-
patients with 
chronic alcohol 
pancreatitis 
age 18-65 years 
Exclusion Criteria 
 
Allergy to propo-
fol or opioid, 
ASA-class greater 
than 3, inability to 
co-operate, drugs 
abuse 
 
Allergy to propo-
fol or opioid, drug 
addiction, inabil-
ity to co-operate, 
ASA class greater 
than 3, patient's 
refusal 
Allergy to propo-
fol or opioid; in-
ability to cooper-
ate; ASA-class 
greater than 3 
 
Allergy to dex-
medetomidine, 
propofol or any 
opioid, ASA-class 
grater when 3 
 
Registration/approval numbers 
NCT NCT01079312 NCT01350037 NCT01070680 NCT01072435 
Eudra CT 2008-007968-42 2009-012398-36 2009-014862-25 2009-015564-34 
Ethics committee 429/13/03/02/08 116/13/03/02/09 249/13/03/02/2009 287/13/03/02/2009 
 
7.3. ERCP 
All patients (studies I-IV) were fasted at least 6 hours before ERCP. Levofloxacine was given orally for anti-
biotic prophylaxis, other premedication was not used. Patients were placed into the prone position. Proce-
dures were performed with the use of duodenoscope (Olympus TJF-160VR) by one of the five senior endo-
scopists. Intestinal lumen was insufflated with air in all studies (I-IV). At the end of ERCP endoscopists 
evaluated ERCP degree of difficulty and ease of performance with the use of structured questionnaire 
(Chutkan RK et al. 2006, Gillham M et al. 2001).     
 
7.4. Administration of Sedation 
7.3 ercp
All patients (studies I-IV) were fasted at least 6 hours before ERCP. Levofloxacine 
was given orally for antibiotic prophylaxis, other premedication was n t used. 
Patients were placed into the prone position. Procedures were performed with the 
use of duodenoscope (Olympus TJF-160VR) by one of the five senior endoscopists. 
Intestinal lumen was insufflated with air in all studies (I-IV). At the end of ERCP 
endoscopists evaluated ERCP degree of difficulty and ease of performance with the 
use of structured questionnaire (Chutkan RK et al. 2006, Gillham M et al. 2001).  
7.4 adminiStration of Sedation
After placement of intravenous cannula infusion of Ringer-acetate was started at the 
rate of 300 ml · h-1. All patients received glycopyrrolate 0.2 mg and lidocaine 20mg 
intravenously five minutes before the start of procedure. Lidocaine 10 mg · ml-1 was 
sprayed into the pharynx to achieve pharyngeal anesthesia. Supplemental oxygen 
was administered to all patients at rate 4 l · min-1. All procedures were performed 
under sedation with maintained spontaneous respiration and unprotected airways 
as follows. 
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7.4.1 patient-controlled Sedation
Self-administration of propofol or propofol and opioid mixture (PCS) was used by the 
patients in all studies (I-IV). A syringe pump connected with administration button 
(Syramed µSP6000™, Arcomed AG, Regensdorf, Switzerland) was programmed 
to deliver 1 ml single bolus dose. Lockout time was adjusted to “zero”, dose-
limitation and background infusion were not used. Sedative mixtures were prepared 
immediately before the procedure (Table 3).
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7.4.1. Patient-controlled sedation 
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(I-IV). A syringe pump connected with administration button (Syramed µSP6000™, Arcomed AG, Regens-
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Table 3 Sedative mixtures for PCS used in the studies I-IV 
 I II III IV 
propofol 10 mg · ml-1 , ml 20 20 20 20 50 40 
alfentanil 0.5 mg · ml-1, ml - 2 - 4 - 6 
remifentanil 0.05 mg · ml-1, ml 5 - 5 - - - 
NaCl 0.9 mg · ml-1, ml - 3 - 1 - 4 
Patients were instructed to use self-administration device every time when they would feel pain or discomfort 
or wanted to be more deeply sedated. The patients were advised to take few doses for the induction of seda-
tion before the start of ERCP. Patients were asked to take 1-2 additional doses if nociceptive stimulus (e.g. 
dilatation of biliar or pancreatic tract) was anticipated during the procedure. If patient became restless, lost 
co-operation and markedly affect procedure performance, propofol boluses 20-30 mg were administered by 
the anesthesiologist and, if needed, infusion of propofol was started. PCS was considered as failed if any pro-
pofol was administered by the anesthesiologist in patients using PCS. 
7.4.2. Anesthesiologist administered sedation 
In studies I and III sedation was managed by anesthesiologist in control groups. In study I sedation was initi-
ated with propofol 40 mg and fentanyl 0.05 mg boluses and maintained with propofol infusion at the rate 
of 0.5 - 9 mg · kg-1 · h-1. If needed, propofol 20 - 40 mg and/or fentanyl 0.05 mg boluses were given during 
the procedure. 
P ti nts were instruct  to use self-administration devic  every time when they 
would feel pain or discomfort or wanted to be more deeply sedated. The patients 
were advised to take few doses for the induction of sedation before the start of 
ERCP. Patients were asked to take 1-2 additional doses if nociceptive stimulus 
(e.g. dil tation of biliar or pancreatic t act) was anticipated during the procedur . 
If patient became restless, lost co-operation and markedly affect procedure 
performance, propofol boluses 20-30 mg were administered by the anesthesiologist 
and, if needed, infusion of propofol was started. PCS was considered as failed if any 
propofol was administered by the anesthesiologist in patients using PCS.
7.4.2 aneStheSiologiSt adminiStered Sedation
In studies I and III sedation was managed by anesthesiologist in control groups. 
In study I sedation was initiated with propofol 40 mg and fentanyl 0.05 mg 
boluses and maintained with propofol infusion at the rate of 0.5 - 9 mg · kg-1 · h-1. 
If needed, propofol 20 - 40 mg and/or fentanyl 0.05 mg boluses were given during 
the procedure.
In study III propofol was administered with the use of TCI. ERCP was started 
after achievement of effect-site concentration (CE) 2 mcg · ml 
-1 using Schnider 
pharmacokinetic model. CE was adjusted with increments of 0.5 mcg · ml 
-1 in order 
to avoid deep sedation. Alfentanil (0.5 mg) bolus was given if signs of inadequate 
analgesia (grimace, increase of more than 30 % in the heart rate, patient’s request) 
occurred during therapeutic intervention (e.g. stricture dilatation).
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7.4.3 dexmedetomidine infuSion
In study IV patients from the intervention group received dexmedetomidine 
infusion. Loading dose 1 mcg · kg-1 was infused in 10 minutes before start of ERCP. 
Thereafter maintenance infusion at the constant rate of 0.7 mcg · kg-1 was used until 
the end of procedure. Patients from control group received placebo at the same rate. 
7.5 meaSurementS
After arrival to the procedural room standard monitoring for deep sedation was 
applied: continuous ECG, HR, NIBP at five minute interval, and SpO2. Additionally 
partial pressure of EtCO2 via nasal cannula and sedation levels were monitored. 
Sedation levels were defined and registered at five minute interval with the use of 
MOAA/S, Ramsay, Gillham and Richmond Agitation-Sedation scales (Table 4).
7.5.1 primary outcome meaSure
In all studies consumption of propofol (mg) was the primary outcome measure. At 
the end of ERCP administration of all sedative drugs was discontinued and total 
amount of propofol, received by the patients, was calculated.
7.5.2 Secondary outcome meaSureS 
Cardiorespiratory values, sedation levels, the incidence of SRAE (see below), success 
rate of PCS (see below), opioid consumption, difficulty of procedure performance, 
patient satisfaction with sedation, quickness of the recovery, intensity of post-
procedural pain, and occurrence of nausea were considered as secondary outcome 
measures in all studies. Additionally, dexmedetomidine consumption was the 
secondary outcome measure in the study IV. 
Desaturation (SpO2< 90 %), pulmonary aspiration, respiratory depression 
(respiratory rate ≤ 6·min-1), hypotension (systolic blood pressure < 90 mmHg),and 
arrhythmia were identified as possible SRAE. Sedation was considered as successful 
if ERCP was not interrupted due to sedation related complication and/or propofol 
was not administered by an anesthesiologist for patients used PCS. Following 
classification (Chutkan RK et al. 2006) was used by endoscopists for evaluation of 
degree of difficulty of ERCP: Grade 1: diagnostic cholangiogram or pancreatogram, 
biliary or pancreatic brush cytology, standard sphincterotomy, removal of < 10 
mm stones, stricture dilatation/stent for extrahepatic stricture or bile leak; Grade 
2: removal of > 10 mm common bile duct stones, stricture dilatation/stent for 
hilar tumors or benign intrahepatic strictures, diagnostic cholangiogram or 
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pancreatogram with BII anatomy, minor papilla cannulation; Grade 3: any therapy 
to biliary duct with BII anatomy, removal of intrahepatic stones or any stones with 
lithotripsy, all pancreatic therapy. Sedation levels were evaluated with the use of 
sedation scales (Table 4). Intensity of post-procedural pain was measured with 
verbal rating scale: 0 = no pain, 1= mild pain, 2 = moderate pain, 3 = severe pain, 4 
= very severe pain. A seven-step numeric range Likert scale (1 = awfully unsatisfied, 
2 = unsatisfied, 3 = almost unsatisfied, 4 = I don’t know, 5 = almost satisfied, 6 = 
satisfied, 7 = awfully satisfied) was applied for measurement of patient´s satisfaction 
with sedation. Also patients were asked about their preference for received sedation 
in case of new ERCP. Quickness of the recovery was evaluated with Aldrete scale 
(Aldrete JA 1995).
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Table 4 Sedation scores used in the studies I-IV 
Response Score 
Ramsay sedation score (Ramsay M et al. 1974)  
Patient paralyzed, unable to assess level of sedation 0 
Patient anxious, agitated, or restless 1 
Patient co-operative, oriented, and tranquil 2 
Patient sedated but responds to commands 3 
Patient asleep but responds to glabellar tap 4 
Patient asleep, responds to nail bed pressure 5 
Patient asleep, no response to nail bed pressure 6 
Gillham sedation score (Gillham M et al. 2001)  
Awake and anxious 1 
Awake not anxious 2 
Speech slurred 3 
Eyes closed, responds to speech 4 
Eyes closed, responds to shaking 5 
Unresponsive 6 
MOAA/S (Manyam S et al. 2007)  
Responds readily to name spoken in normal tone 5 
Lethargic respose to name spoken in normal tone 4 
Responds only after name is called loudly and/or repeatedly 3 
Responds only after mild prodding or shaking 2 
Does not respond to mild prodding or shaking 1 
Does not respond to noxious stimulus 0 
Richmond Agitation-Sedation Scale (RASS) (Ely EW et al. 2007)  
Description Term score 
Overtly combative,violent,immediate danger to staff Combative +4 
Pulls or removes tube(s),catheter(s);aggressive Very agitated +3 
Frequent nonpurposeful movemen,fights ventilator Agitated +2 
Anxious but movements not aggressive or vigorous Restless +1 
Alert and calm  0 
Not fully alert, but has sustained awakening(eye opening to 
voice >10 sec.) 
Drowsy -1 
Briefly awakens with eye contact to voice <10 sec Light sedation -2 
Movement or eye opening to voce(but no eye contact) Moderate sedation -3 
No response to voice, but movement or eye opening to 
physical stimulation 
Deep sedation -4 
No response to voice or physical stimulation Unarousable -5 
 
7.5.1. Primary outcome measure 
In all studies consumption of propofol (mg) was the primary outcome measure. At the end of ERCP admin-
istration of all sedative drugs was discontinued and total amount of propofol, received by the patients, was 
calculated. 
7.5.2. Secondary outcome measures  
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7.5.3 propofol plaSma concentrationS
In study I blood samples were obtained randomly from ten patients in both 
groups before ERCP began, after papilla cannulation and at the end of ERCP. 
Obtained blood samples were stored in ice thereafter plasma was separated and 
frozen. Propofol concentrations were determined by high-performance liquid 
chromatography with fluorescence detection in the Laboratory of the Department 
of Clinical Pharmacology, Helsinki University Central Hospital, Meilahti (Plummer 
G 1987). The detection limit of the assay was 0.5 mcg · l-1 and the day-to-day CV 
2.83-8.13 %.
7.6 StatiStical analySiS
Sample sizes were calculated to achieve statistical power of 80 % (alpha=0.05, 
SD=85 mg) to detect 100 mg (study I) or 70 mg (studies II-IV) difference in the 
consumption of propofol between the groups. Possible incomplete studies due 
to sedation adverse events and cancellations were considered in the sample size 
calculation. 
Normality of data distribution was tested with Kolmogorov-Smirnov test. 
Continuous normally distributed data were compared with a two-tailed t-test 
and data with abnormal distribution with Mann-Whitney U-test. A general linear 
modeling for repeated measures was used to detect statistical differences in 
cardiorespiratory values and sedation scores between the groups. Differences in 
categorical variables were tested with Fisher’s exact test or with Fisher-Freeman-
Halton test. Bonferroni correction was used in multiple comparisons (study III) 
by adjusting the local significance level from P < 0.05 to P < 0.025 i.e. maximum 
two comparisons. Two-sided P-values are used. All statistics in studies II and II 
were performed with PASW 18 (SPSS Inc.) and IBM SPSS (v20, IBM Corporation, 
New York, NY)  
7.7 ethical conSiderationS
All Studies were conducted according to the revised Declaration of Helsinki (WMA 
2008), and were approved by by the Institutional Ethics committee of Helsinki 
University Central Hospital and The Finnish National Agency for Medicines. All 
patients gave their written informed consent before entering the studies.
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8 results
performed ercp
ERCP was performed for all patients as planned. Performed ERCP characteristics 
are shown in the Table R1.
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8. Results 
Performed ERCP 
ERCP was performed for all patients as planned. Performed ERCP characteristics are shown in the Table R1. 
Table R1  Performed ERCP 
 I II III IV 
ERCP duration, min mean (SD) 24(13) 25(14) 24(13) 24(13) 
Degree of difficulty 1 / 2 / 3 (Chutkan RK et 
al. 2006) 46 / 3 / 33 53 / 7 / 21 53 / 10 / 16 7 / 1 / 42 
ERC, common bile duct stone extraction (n) 6 20 12 3 
Biliary/pancreatic stent place-
ment/exchange/removal   (n) 46 37 28 38 
Biliary/ pancreatic sphincterotomy   (n) 40 52 36 20 
Pneumatic dilatation of biliary/ pancreatic 
duct  (n) 20 25 11 23 
The ease of ERCP performance did not differ between the study groups (Table R2). Two procedural compli-
cations occurred: blood vessel perforation with guide wire and duodenum perforation. Both of these cases 
were treated conservatively and had uneventful recovery. ERCP was interrupted in one patient for sedation 
reason (marked breathing depression in patient sedated with propofol-remifentanil PCS (I)). 
Table R2  The ease of ERCP performance, mean (SD) 
Study I II III IV 
Study arm PCS PI R A1 A2 PCS TCI DEX PLC 
The ease of ERCP 
perform. (mean (SD) 8.0 (2.4) 7.8 (2.8) 7.9 (1.7) 8.8 (2.5) 8.0 (2.3) 8.5(2.3) 9.3(3.0) 8.8 (2.7) 8.2 (2.2) 
 
Consumption of propofol 
The consumption of propofol was significantly different between study groups in studies I, III, IV and did not 
differ significantly in study II (Table R3). 
 
 
 
The ease of ERCP performance did not differ between the study groups (Table 
R2). Two procedural complications occurred: blood vessel perforation with guide 
wire and duodenum perforation. Both of these cases were treated conservatively 
and had uneventful recovery. ERCP was interrupted in on  patient for sedation 
reason (marked breathing depression in patient sedated with propofol-remifentanil 
PCS (I)).
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co S ion of propofol
The consumption of propofol was significantly different between study groups in 
studies I, III, IV and did not differ significantly in study II (Table R3).
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Table R3  Propofol consumption (mg) during  ERCP, mean (SD) 
Study I II III IV 
Study arm PCS PI R A1 A2 PCS TCI DEX PLC 
Propofol con-
sumption, mg 
mean (SD) 
175 (98) 249 (138) 177(105) 197 (88) 162 (70) 224(101) 306(124) 116 (61) 159 (72) 
 
Consumption of opioid 
In the studies I-III opioid consumption did not differ significantly between the groups (table R4). Significant 
(P=0.008) difference in alfentanil consumption was founded between dexmedetomidine and placebo groups 
in study IV. The mean difference between the groups was 0.43 mg (95 % CI; 0.1- 0.6 mg).   
Table R4  Consumption of opioid , mean(SD) 
Study Study arm fentanyl alfentanil remifentanil 
I PCS ---- ---- 0.2 (0.1) mg 
PI 0.1 (0.03) mg ---- ---- 
II R ---- ---- 0.05 (0.03) mg 
A1  ---- 1.1 (0.5) mg ---- 
A2  ---- 1.5 (0.8) mg ---- 
III PCS ---- 0.5(0.4) mg ---- 
TCI ---- 0.5(0.4) mg ---- 
IV Dex ---- 0.8 (0.4) mg* ---- 
Placebo ---- 1.2 (0.6) mg ---- 
PI-propofol infusion, R-remifentanil 0.01 mg·ml-1, A1- alfentanil 0.04 mg·ml-1, A2 - alfentanil 0.08 
mg·ml-1, Dex-dexmedetomidine, *significant difference in alfentanil consumption between dexmede-
tomidine and placebo groups, P=0.008 
 
PCS success rate 
The mean (SD) success rate of PCS in all studies was 92(3) % .Detailed success rate of PCS is shown in the 
Table R5. 
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In the studi s I-III opioid nsumption did ot differ significantly between the groups 
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pcS SucceSS rate
The mean (SD) success rate of PCS in all studies was 92(3) %. Detailed success rate 
of PCS is shown in the Table R5.
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Table R5  PCS success rate 
Study I II III IV 
Study arm PCS R A1 A2 PCS DEX PLC 
success rate of 
PCS among 
study arms,%(n) 
93 % (38/41) 89% (24/27) 
93% 
(25/27) 
93% 
(25/27) 93 % (38/41) 
76 % 
(19/25) 
100% 
(25/25) 
average success 
rate, mean 
(SD)% (n) 
95 % (38/40) 92(2) % (74/81) 93 % (38/41) 88(17) % (44/50) 
Among the failed PCS cases 12 patients received additional propofol boluses and in 5 patients sedation was 
converted to the anesthesiologist-managed propofol infusion and in one case ERCP was interrupted because 
of the respiratory depression. 
 
Sedation levels 
In the study I sedation levels were significantly (P < 0.0001) lighter in patients receiving PCS than in control 
group (propofol infusion) (Fig 1A). In the study II sedation levels during ERCP did not differ significantly 
between the study groups (Fig 1B). In the study III sedation levels were significantly deeper in the group re-
ceiving propofol TCI at 10, 15, 20, and 25 minutes intraprocedurally, P = 0.002 - 0.035 (Fig 1C). In the study 
IV sedation levels were significantly deeper in patients receiving dexmedetomidine than in control (placebo) 
group, P= 0.021-0.032 (Fig 1D). 
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Among the failed PCS cases 12 patients received additional propofol boluses 
and in 5 patients sedation was converted to the anesthesiologist-managed propofol 
infusion and in one case ERCP was interrupted because of the respiratory depression.
Sedation levelS
In the study I sedation levels were significantly (P < 0.0001) lighter in patients 
receiving PCS than in control group (propofol infusion) (Fig 1A). In the study II 
sedation levels during ERCP did not differ significantly between the study groups 
(Fig 1B). In the study III sedation levels were significantly deeper in the group 
receiving propofol TCI at 10, 15, 20, and 25 minutes intraprocedurally, P = 0.002 
- 0.035 (Fig 1C). In the study IV sedation levels were significantly deeper in 
patients receiving dexmedetomidine than in control (placebo) group, P= 0.021-
0.032 (Fig 1D).
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Fig. 1A Sedation levels during ERCP (I)
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figure 1a.  Sedation levels during ERCP(I). *Significant differnce observed between PCS and PI at 5,10,15,20 
minutes intraprocedurally and at the end of ERCP, P < 0.0001.PCS-patient-controlled sedation, PI-propofol 
infusion. MOAA/S - Modified Observer’s Assessment of Alertness and Sedation: 5-Responds readily to name 
spoken in normal tone, 4-Lethargic response to name spoken in normal tone, 3-Responds only after name 
is called loudly and/or repeatedly, 2-Responds only after mild prodding or shaking, 1-Does not respond to 
mild prodding or shaking, 0-Does not respond to noxious stimulus.
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Fig. 1B Sedation levels during ERCP (II)
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A 0.04 mg/ml
figure 1b.  Sedation levels during ERCP(II). R-remifentanil 0.01 mg · ml-1; A 0.04 mg/ml-alfentanil 0.04 mg 
· ml-1; A 0.08 mg/ml-alfentanil 0.08 mg · ml-1; MOAA/S - Modified Observer’s Assessment of Alertness 
and Sedation: 5-Responds readily to name spoken in normal tone, 4-Lethargic response to name spoken 
in normal tone, 3-Responds only after name is called loudly and/or repeatedly, 2-Responds only after mild 
prodding or shaking,1-Does not respond to mild prodding or shaking, 0-Does not respond to noxious stimulus.
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figure 1c.  Sedation levels during ERCP(III). *Significant differnce observed between PCS and TCI groups at 
10,15,20 minutes intraprocedurally, P < 0.05.PCS-patient-controlled sedation, TCI-target-controlled infusion, 
MOAA/S - Modified Observer’s Assessment of Alertness and Sedation: 5-Responds readily to name spoken 
in normal tone, 4-Lethargic response to name spoken in normal tone, 3-Responds only after name is called 
loudly and/or repeatedly, 2-Responds only after mild prodding or shaking, 1-Does not respond to mild 
prodding or shaking, 0-Does not respond to noxious stimulus.
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figure 1d.  Sedation levels during ERCP(IV). *Significant differnce observed between PLC and Dex groups at 
5,10,15,20 minutes intraprocedurally and at the end of ERCP, P < 0.05. PLC-placebo, Dex-dexmedetomidine, 
MOAA/S - Modified Observer’s Assessment of Alertness and Sedation: 5-Responds readily to name spoken 
in normal tone, 4-Lethargic response to name spoken in normal tone, 3-Responds only after name is called 
loudly and/or repeatedly, 2-Responds only after mild prodding or shaking, 1-Does not respond to mild 
prodding or shaking, 0-Does not respond to noxious stimulus.
vital SignS
In the study I mean respiratory rate was significantly higher in patients receiving 
propofol infusion than in patients receiving PCS, P < 0.05. In the study II significant 
difference in the mean respiratory rate (P = 0.006) and in the mean arterial pressure 
(P = 0.0247) was observed between patients receiving remifentanil and alfentanil in 
concentration 0.04 mg · ml-1. In the study IV mean heart rate was significantly higher 
in the group receiving placebo (P<0.001). Other marked differences in vital signs 
were not founded between the study groups (Figures 2 A-D, 3A-D, 4 A-D, 5 A-D). 
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Fig.2A  Heart rate during ERCP (I)
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figure 2a.  Heart rate during ERCP(I). PCS-patient-controlled sedation, PI-propofol infusion.
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Fig. 2B Heart rate during ERCP (II)
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figure 2b.  Heart rate during ERCP(II). R-remifentanil 0.01 mg · ml-1; A 0.04 mg/ml-alfentanil 0.04 mg · 
ml-1; A 0.08 mg/ml-alfentanil 0.08 mg · ml-1.
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figure 2c.  Heart rate during ERCP(III). PCS-patient-controlled sedation, TCI-target-controlled infusion.
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figure 2d.  Heart rate during ERCP(IV). *Significant differnce observed between PLC and Dex groups 
during the procedure, P < 0.05. PLC-placebo, Dex-dexmedetomidine.
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figure 3a.  Systolic arterial pressure during ERCP(I). PCS-patient-controlled sedation, PI-propofol infusion.
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figure 3b.  Mean arterial pressure during ERCP(II). *Significant differnce observed between R and A 0.04 
mg/ml at 5,10,20 minutes intraprocedurally, P < 0.05.R-remifentanil 0.01 mg · ml-1; A 0.04 mg/ml-alfentanil 
0.04 mg · ml-1; A 0.08 mg/ml-alfentanil 0.08 mg · ml-1.
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figure 3c.  Mean arterial pressure during ERCP(III). PCS-patient-controlled sedation, TCI-target-controlled 
infusion.
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figure 3d.  Mean arterial pressure during ERCP(IV). PLC-placebo, Dex-dexmedetomidine.
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figure 4a.  Peripheral oxygen saturation during ERCP(I). PCS-patient-controlled sedation, PI-propofol 
infusion.
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figure 4b.  Peripheral oxygen saturation during ERCP(II). R-remifentanil 0.01 mg · ml-1; A 0.04 mg/ml-
alfentanil 0.04 mg · ml-1; A 0.08 mg/ml-alfentanil 0.08 mg · ml-1.
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figure 4c.  Peripheral oxygen saturation during ERCP(III). PCS-patient-controlled sedation, TCI-target-
controlled infusion.
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figure 4d.  Peripheral oxygen saturation during ERCP(IV). PLC-placebo, Dex-dexmedetomidine.
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figure 5a.  Respiratory rate and partial end-tidal carbon dioxide concentration during ERCP (I). *Significant 
differnce observed between PCS and PI intraprocedurally and at the end of ERCP, P < 0.05. PCS-patient-
controlled sedation, PI-propofol infusion.
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figure 5b.  Respiratory rate and partial end-tidal carbon dioxide concentration during ERCP(II). *Significant 
differnce observed between R and A 0.04 mg/ml at 5,10,15,20 minutes intraprocedurally, P < 0.05. 
R-remifentanil 0.01 mg · ml-1;  A 0.04 mg/ml-alfentanil 0.04 mg · ml-1;  A 0.08 mg/ml-alfentanil 0.08 mg · ml-1.
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figure 5c.  Respiratory rate and partial end-tidal carbon dioxide concentration during ERCP(III). PCS-
patient-controlled sedation, TCI-target-controlled infusion.
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figure 5d.  Respiratory rate and partial end-tidal carbon dioxide concentration during ERCP(IV). PLC-
placebo, Dex-dexmedetomidine.
43
Srae (pcS)
212 patients were sedated with the use of PCS in the studies I-IV. Severe respiratory 
depression requiring procedure interruption and bag-mask ventilation occurred in 
one (0.5 %) patient sedated with propofol-remifentanil PCS (I). Desaturations and 
mild respiratory depression were observed in 26(12 %) of patients. All desaturations 
were treated with oxygen flow increase to 8 l · min-1. Additionally nasal airway 
and chin lift manoeuvre were used each in four patients. Tracheal intubation was 
not needed for any patient. Severe hypotension occurred in one patient sedated 
with combination of PCS and dexmedetomidine. Oversedation (MOAA/S=1) was 
observed in 96(45 %) patients. The incidence of SRAE did not differ significantly 
between patients receiving PCS and control groups (AAS). In the study III all 
sedation related adverse events were associated with combination of propofol and 
alfentanil (P=0.03). Arrhythmia and pulmonary aspiration were not observed. 
Srae (control groupS)
In control groups sedation was administered by the anesthesiologist for 81 patients 
with the use of anesthesiologist-adjusted propofol infusion (study I) or target-
controlled propofol infusion (study III).All sedations in study I were uneventful. 
In the study III desaturations were observed in 7(17 %), chin lift maneuver was used 
in 3(7 %) patients. Hypotension occurred in 1(2 %) patient. All SRAE occurred in 
patients treated with combination of propofol and alfentanil. Oversedation (MOAA/
S=1) was observed in 50(62 %) patients. Arrhythmia and pulmonary aspiration 
were not observed.
targeted and meaSured propofol concentrationS
When propofol administered with TCI the mean targeted propofol concentration 
was 2.2 (0.4) mcg · ml-1 needed for optimal sedation (III). In a random sample of 
patients (I) 52 blood samples were obtained (Table R6). The mean (SD) propofol 
plasma concentration did not differ significantly between the study groups and 
was 2.6(1.6) mcg · ml-1 (papilla cannulation, PC), 1.1(0.3) mcg · ml-1 (end of ERCP, 
EE) and 1.5(0.5) mcg · ml-1(PC) 1.0(0.5) mcg · ml-1(EE) in the propofol infusion and 
PCS groups respectively. 
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was 2.6(1.6) mcg · ml-1 (papilla cannulation, PC), 1.1(0.3) mcg · ml-1 (end of ERCP, EE) and 1.5(0.5) mcg · 
ml-1(PC) 1.0(0.5) mcg · ml-1(EE) in the propofol infusion and PCS groups respectively.  
Table R6  Cp of propofol during ERCP 
 PI (n=10) PCS (n=8) 
baseline 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
papilla cannulation 
1.9 1.6 1.0 2.5 2.2 1.1 4.2 1.7 6.0 3.6 2.4 - 1.1 - 1.6 0.8 1.4 1.5 
end of ERCP 
0.9 1.0 0.7 1.6 0.8 1.0 1.0 1.4 1.0 1.2 0.7 0.4 0.5 1.8 0.9 1.5 1.2 0.8 
 
Recovery  
Sedation levels during recovery 
In study I sedation levels were significantly deeper in the control group (propofol infusion) than in the PCS 
group after termination of ERCP and until twenty minutes post-procedurally. Also in study III sedation levels 
were significantly (P = 0.047) deeper in patients sedated by the anesthesiologist with the use of target-
controlled infusion until 15 minutes post procedurally. In study IV patients sedated with combination of 
dexmedetomidine and PCS sedation levels were significantly deeper sedated until 20 minutes post-
procedurally. In study II sedation levels did not differ markedly between study groups at the end of ERCP 
and during the recovery (Figures 6 A-D). 
recovery 
Sedation levels during recovery
In study I sedation levels were significantly deeper in the control group (propofol 
infusion) than in the PCS group after termination of ERCP and until twenty minutes 
post-procedurally. Also in study III sedation levels were significantly (P = 0.047) 
deeper in patients sedated by the anesthesiologist with the use of target-controlled 
infusion until 15 minutes post procedurally. In study IV patients sedated with 
combination of dexmedetomidine and PCS sedation levels were significantly deeper 
sedated until 20 minutes post-procedurally. In study II sedation levels did not 
differ markedly between study groups at the end of ERCP and during the recovery 
(Figures 6 A-D).
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figure 6a.  Sedation levels during recovery (I). *Significant differnce observed between PCS and PI during 
early 10 minutes in the recovery room, P < 0.05. PCS-patient-controlled sedation, PI-propofol infusion. 
Gillham sedation score: Awake and anxious-1, Awake not anxious-2, Speech slurred-3, Eyes closed, responds 
to speech-4, Eyes closed, responds to shaking-5, Unresponsive-6.
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Fig. 6B Sedation levels recovery (II)
R
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A 0.04 mg/ml
figure 6b.  Sedation levels during recovery (II). R-remifentanil 0.01 mg · ml-1; A 0.04 mg/ml-alfentanil 0.04 
mg · ml-1; A 0.08 mg/ml-alfentanil 0.08 mg · ml-1. Gillham sedation score: Awake and anxious-1, Awake 
not anxious-2, Speech slurred-3, Eyes closed, responds to speech-4, Eyes closed, responds to shaking-5, 
Unresponsive-6.
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figure 6c.  Sedation levels during recovery(III). *Significant differnce observed between PCS and TCI during 
early 5 minutes in the recovery room, P < 0.05. PCS-patient-controlled sedation, TCI-target-controlled 
infusion. Gillham sedation score: Awake and anxious-1, Awake not anxious-2, Speech slurred-3, Eyes closed, 
responds to speech-4, Eyes closed, responds to shaking-5, Unresponsive-6.
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figure 6d.  Sedation levels during recovery(IV). *Significant differnce observed between PLC and Dex during 
early 20 minutes in the recovery room, P < 0.05. PLC-placebo, Dex-dexmedetomidine. Gillham sedation 
score: Awake and anxious-1, Awake not anxious-2, Speech slurred-3, Eyes closed, responds to speech-4, 
Eyes closed, responds to shaking-5, Unresponsive-6.
Rapidity of recovery 
The recovery of all patients in studies I-IV received propofol or propofol-opioid 
sedation was very fast. Near 90 % of patients were ready to discharge from the 
recovery room 10 minutes after ERCP termination. Aldrete scores did not differ 
markedly between study groups in studies I-III. In the study IV patients sedated 
with combination of dexmedetomidine and PCS had significantly (P = 0.011) lower 
Aldrete scores than sedated with PCS only until 5 minutes post-procedurally.
poSt-procedural pain and nauSea
The intensity of post-procedural pain was low in all patients after ERCP and did 
not differ between the treatment groups in studies I-III (Figures 7 A-C).
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figure 7a .  Pain intensity during recovery (I). PCS-patient-controlled sedation, PI-propofol infusion. Intensity 
of post-procedural pain (verbal rating scale): 0 = no pain, 1= mild pain, 2 = moderate pain, 3 = severe pain, 
4 = very severe pain.
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Fig. 7B Pain during recovery (II)
R
A 0.08 mg/ml
A 0.04 mg/ml
figure 7b.  Sedation levels during recovery (II). R-remifentanil 0.01 mg · ml-1; A 0.04 mg/ml-alfentanil 0.04 
mg · ml-1; A 0.08 mg/ml-alfentanil 0.08 mg · ml-1. Intensity of post-procedural pain (verbal rating scale): 0 
= no pain, 1= mild pain, 2 = moderate pain, 3 = severe pain, 4 = very severe pain.
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Fig. 7C Pain during recovery (III)
TCI
PCS
figure 7c.  Pain intensity during ERCP(III). PCS-patient-controlled sedation, TCI-target-controlled infusion. 
Intensity of post-procedural pain (verbal rating scale): 0 = no pain, 1= mild pain, 2 = moderate pain, 3 = 
severe pain, 4 = very severe pain.
Patients who received dexmedetomidine had significantly less pain than those who 
received placebo in the study IV (Figure 7 D).
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figure 7d.  Pain intensity during recovery(IV). *Significant differnce observed between PLC and Dex during, 
P < 0.05. PLC-placebo, Dex-dexmedetomidine. Intensity of post-procedural pain (verbal rating scale): 0 = 
no pain, 1= mild pain, 2 = moderate pain, 3 = severe pain, 4 = very severe pain.
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Nausea occurred in 21/212 (10 %) patients sedated with the use of PCS and in 
7/81(8.6 %) patients from control groups (anesthesiologist administered propofol). 
In study II nausea happened significantly more often (P=0.044), in patients received 
remifentanil than in those sedated with the combination of alfentanil and propofol. 
patient SatiSfaction with Sedation and preference 
for received Sedation 
In all studies (I-IV) patient satisfaction was high (table R6) and did not differ 
significantly between study groups. Among patients who received PCS 198/212 
(93 %) of patients would prefer PCS as a sedation method if ERCP will be repeated 
in future. Also in control groups preference for received sedation was 75/81(93 %).
60 
 
 
Table R6 Patient’s satisfaction with sedation and preference for received sedation 
Study I II III IV 
Study arm PCS PI R A1 A2 PCS TCI DEX PLC 
Patient satisfac-
tion (mean (SD) 6.7 (0.5) 6.8 (0.5) 6.4 (1.2) 6.4 (0.7) 6.7 (0.5) 6.5(0.7) 6.6(0.7) 6.3 (0.7) 6.0 (1.3) 
Preference in 
future Y/ N / 
don’t know  (n) 
40 /0 /0 40 /0 /0 25 /1 /1 25 /0 /3 26 /0 /1 36 /1/1 35/3 /3 24 / 0 /1 22 / 2 /1 
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9 discussion
the SuitaBility of pcS for ercp
The results of studies I-IV showed that PCS is a very acceptable method of sedation 
for ERCP. The mean success rate of PCS, defined as lack of an anesthesiologist’s 
adherence to the patient’s sedation, in the studies I-IV was 92 %, which is 
substantially higher than that in two previous studies (Jowell PS et al. 1996, 
Gillham et al. 2001) describing PMS during ERCP. However, in these studies either 
midazolam or PMS with TCI was used. Using propofol alone or in the combination 
with remifentanil or alfentanil, the success rate of PCS during ERCP is comparable 
to that during colonoscopy (Crepeau T et al. 2005). The patient´s and procedural 
factors predisposing failure of PCS are needed to reveal in the future. Our hypothesis 
that chronic alcohol abuse predispose to the failure of PCS could not be supported 
by the results of the study IV. 
propofol conSumption
The results of studies (I, III) showed that in comparison to the AAS either with the 
use of manually adjusted or target-controlled propofol infusion, implementation of 
PCS leads to significant reduction of propofol consumption during ERCP. Although 
randomized comparisons between different methods of propofol administration 
during ERCP are lacking, this observation is in accordance with previous comparisons 
of AAS with PCS during endoscopy (Mandel J et al. 2008, Mandel J et al. 2010). 
In the study of Heuss, comparing PCS with the nurse administered propofol 
sedation (NAPS) during colonoscopy propofol consumption was somewhat higher in 
patients received PCS (Heuss L 2004). At least few points needed to be considered in 
interpretation of this finding. Firstly, propofol boluses were used for sedation in the 
NAPS group. It was shown previously that in comparison to propofol infusion, bolus 
administration technique is associated with reduced consumption of propofol. On 
the other hand sedation with intermittent propofol boluses might be inappropriate 
during long-lasting ERCP (Newson C et al. 1995). Secondly, duration of colonoscopy 
was shorter in the NAPS groups and thirdly, significant difference between the study 
groups in propofol consumption was not achieved.  
In study II propofol consumption did not differ between patients received 
remifentanil and alfentanil. The remifentanil and alfentanil doses used in the current 
study may have been equipotent. The true equianalgesic doses of remifentanil and 
alfentanil have not been defined previously in sedation with spontaneous respiration. 
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During propofol GA with the use of substantially higher doses of opioids than in 
PCS with spontaneous respiration, remifentanil appeared equipotent to alfentanil 
in rates 1:4 to 1:20 (Philip BK et al. 1997, Jhaveri et al. 1997).    
Anesthetic and analgesic sparing effects of dexmedetomidine are well 
documented (Bulow et al. 2007, Candiotti et al. 2010, Gerlach et al. 2009) in the 
previous studies. In the study IV patients received dexmedetomidine consumed 
significantly less propofol as well.
Sedation related adverSe eventS (Srae)
In the present studies PCS appeared comparable with AAS in terms of adverse 
events and patient satisfaction with sedation. The results of studies I-IV showed 
incidence of 12 % in SRAE that is at the same frequency of those during AAS. Agostoni 
reported retrospectively the incidence of SRAE of 5.3 % in 2207 patients sedated 
with propofol during ERCP (Agostoni M et al. 2011). In the study of Berzin reporting 
prospectively 528 ERCP patients under propofol sedation or general anesthesia the 
incidence of SRAE was 21 % (Berzin T et al. 2008).  
optimal compoSition of Sedative mixture and regime of  
adminiStration for pcS
The results of study II showed that combination of propofol and alfentanil for PCS 
during ERCP produces less respiratory depression and post-procedural nausea than 
combination of propofol and remifentanil. This has not been reported previously. 
Randomized double-blind comparisons of different opioids for PCS are lacking. The 
benefits of opioid addition to propofol in sedative mixture for PCS are still unclear. In 
the majority of studies that describe PCS, either propofol alone or a combination of 
propofol and alfentanil have been used (Jowell P et al. 1996, Gillham M et al. 2001, 
Mandel et al. J 2008, Mandel J et al. 2010, Heuss L et al. 2004). According to these 
studies, adding an opioid increases the quality of sedation and decreases the need 
for interventions during the procedures (Mandel J et al. 2008).  The similar dose 
of remifentanil (10 mcg·ml-1 in the sedative mixture) as has been found effective 
and safe in the previous studies of PCS for lithotripsy and colonoscopy (Mandel J 
et al. 2008, Alhashemi J et al. 2006).
Sedation levelS 
Deep sedation believed to be rather necessary for successful performance of ERCP 
(Chainaki I et al. 2011). The results of studies I-IV showed that if patient can choose 
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the necessary sedation level, deep sedation might be needed only in about 40 % of 
patients. In the studies I and III the decision of the depth of sedation was based on 
the previously established institutional practice or on the targeted CE of propofol, 
and adjustments were made on the basis of physiological observations during the 
procedure. TCI may rationalize the dosing of intravenous anesthetics during general 
anesthesia, but the optimal concentrations of propofol for conscious sedation during 
ERCP remain to be defined. 
The propofol plasma concentrations (PPC) have not been previously measured 
in patients sedated with PCS during ERCP. In the study of Irwin 36 patients treated 
with the use of patient-maintained propofol infusion, optimal sedation was provided 
at median target concentrations of 0.8 – 0.9 mg · ml-¹ during surgical but not 
gastrointestinal procedures (Irwin et al. 1997). This and other studies (Schnider 
et al. 1998, 1999) showed a good correlation between predetermined plasma and 
effect site and actually measured blood propofol concentrations. 
In a randomly chosen sample of patients (I) the actually measured plasma 
concentrations of propofol (2.6 (1.6) mcg · ml-¹) were surprisingly close to needed 
targeted effect-site concentration (2.2(0.4) mcg · ml-¹) (III). Yet there is a large 
variation between the plasma or effect-site concentrations of propofol and the 
optimal sedation both in the previous study (Irwin et al. 1997) and in ours. Although 
significant difference in PPC was not founded between patients received PI and 
PCS there was a tendency to a higher PPC during papilla cannulation in patients 
sedated with PI. Undoubtedly other than drug effects are accounted for the patients´ 
tolerance of procedural discomfort during endoscopy.  
dexmedetomidine aS an adjuvant for pcS
The results of study IV do not support the use of dexmedetomidine for sedation of 
patients with chronic alcohol abuse during ERCP. According to the best of current 
knowledge dexmedetomidine was not previously evaluated for procedural sedation 
of patients with chronic alcohol abuse in randomized controlled trials. The main 
disadvantage of dexmedetomidine in the study IV was significantly extended 
recovery from sedation. This observation is concordant with the study of Muller 
founded that patients sedated with dexmedetomidine during ERCP recovered 
significantly slower than received propofol and fentanyl for sedation (Muller S et 
al. 2008). Also dexmedetomidine might produce unfavorable hemodynamic effects 
such as hypotension and bradycardia (Jalowiecki P et al. 2005). Even though in the 
study IV severe bradycardia did not occurred in patients received dexmedetomidine, 
serious hypotension developed in one (4 %) patient. Because all patients in the 
study IV received glycopyrrolate this agent might be effective in the prevention 
of bradycardia produced by dexmedetomidine. Unstable hemodynamics may 
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be especially dangerous in patients suffered from cardiovascular diseases thus 
restricting dexmedetomidine use in these patients. Patients with cardiovascular 
diseases accounted for near 20 % of patients in the studies I-IV. Other disadvantages 
of dexmedetomidine for ERCP sedation showed in the study IV are long sedation 
induction time and insufficient sedative effect in the recommended administration 
regimen. Thus obvious conclusion should be made that administration of 
dexmedetomidine with the use of loading dose of 1 mcg · kg-1 over 10 minutes followed 
by continuous infusion of 0.7 mcg · kg-1 is inappropriate for sedation of patients 
with chronic alcohol abuse during ERCP. Clinical trials describing other regiments 
of dexmedetomidine administration during ERCP are lacking. Combination of 
dexmedetomidine infusion with self-administered propofol and alfentanil in the 
Study IV showed significant decrease in the success rate of PCS. The nature of 
this phenomenon remains unexplained. Dexmedetomidine believed produce co-
operative sedation but influence of propofol and alfentanil on pharmacodynamics 
of dexmedetomidine is still unstudied. Combination of dexmedetomidine with PCS 
should be avoided. Significant reduction of propofol consumption in the study IV did 
not reduce the incidence of SRAE and thus clinical significance of this observation 
was fully invalidated by prolonged sedation induction time and recovery. 
the uSe of pcS aS an inveStigative tool 
In study IV PCS was successfully used as a rescue sedation method for evaluation 
of dexmedetomidine efficacy during ERCP. To the best of current knowledge such 
application of PCS has not been described previously. So, the utilization of PCS 
might be extended for clinical trials describing efficacy of sedatives or/and sedative 
regiments, local anesthetics, regional anesthesia etc. 
limitationS
This thesis has some limitations. All studies are single-centre trials.  Due to 
relatively small number of patients conclusions regarding the safety of PCS are 
only preliminary. Emergencies and patients in ASA class IV as well as patients 
over 75 of age were not included in the studies. No psychological assessment was 
performed although psychological factors may influence on the individual needs of 
sedation. The design of studies I and III did not allowed double-blind administration 
of sedatives. In study III the discrimination of inadequate analgesia and sedation 
was based on clinical observations. Sedation scales used in studies I-IV are not 
validated for GI endoscopy. Anesthesiologist and anesthetic nurse were present all 
the procedure time. The recovery room personnel were not blinded to the study 
group allocation (studies I and III). 
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10 clinical aPPlications and future studies
On the basis of these findings PCS has been introduced as a primary method of 
sedation for patients undergoing ERCP in the Endoscopy unit in Meilahti hospital. 
Because PCS can be used without an anesthesiologist (Lee et al. 2004, Lee D et 
al. 2002, Kulling D et al. 2001, Heuss L et al. 2004,), this approach could be a 
cost-effective method. In a Finnish questionnaire survey the Finnish anaesthetic 
nurses expressed a very positive attitude on their independent role in the sedation 
outside the operating room (Vakkuri A et al. 2006). The wider use of PCS in the 
surveillance of an anesthetic nurse only, requires a composition of an appropriate 
educational programme, which is currently lacking. The advantages of PCS include 
undoubtedly that the patient can sedate him- or herself both mildly or deeply. In 
addition, PCS can be easily converted to a nurse controlled method when PCS fails. 
However, there is an obvious need for future studies. Studies with sufficient 
amounts of patients must be carried to define the safety of PCS. In large-scale 
studies it would be possible to find out patients, to whom PCS should not be used. 
In addition, there is a lack of studies about the optimal composition of sedative 
mixtures and administration regiments for PCS. Use of lock-out time, background 
infusion and limitation of total dose of sedatives should be more carefully examined. 
Finally, the impact of the structure of infusion device, including the design of patient-
administration button, should be taken into the consideration in the future plans.
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11 conclusions
The following conclusions can be made from the presented data:
1) Although sedation for ERCP could be successfully carried out by an 
anesthesiologist (AAS), patient-controlled sedation (PCS) is associated with 
decreased consumption of propofol, lighter levels of sedation and better recovery 
profile. Also deep sedation could be produced with PCS. Satisfaction rates are 
equal with both PCS and AAS. No difference exists in sedation related adverse 
events between PCS and AAS (I, III). 
2) Remifentanil causes more respiratory depression and nausea than alfentanil. 
The optimal concentration of alfentanil for PCS is 0.04 mg · ml-1 (II).
3) PCS is a suitable method of sedation of alcoholics during ERCP. Adding of 
dexmedetomidine to PCS reduces the consumption of propofol but impairs 
the quality of sedation, results in deeper level of sedation and delays recovery 
in comparison to PCS only (IV). 
4) The success rate of PCS during ERCP is 88 - 100 % in selected patients (I-IV).
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